A patent review of selective CDK9 inhibitors in treating cancer

References

• Roskoski R. Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs. Pharmacol Res. 2019;139:471–488.
   PubMed Web of Science ®Google Scholar
• Panagiotou E, Gomatou G, Trontzas IP, et al. Cyclin-dependent kinase (CDK) inhibitors in solid tumors: a review of clinical trials. Clin Transl Oncol. 2022;24(2):161–192. DOI:10.1007/s12094-021-02688-5
   PubMed Web of Science ®Google Scholar
• Zhang M, Zhang L, Hei R, et al. CDK inhibitors in cancer therapy, an overview of recent development. Am J Cancer Res. 2021;11(5):1913–1935.
   PubMed Web of Science ®Google Scholar
• Lapenna S, Giordano A. Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009;8(7):547–566.
   PubMed Web of Science ®Google Scholar
• Cheng W, Yang Z, Wang S, et al. Recent development of CDK inhibitors: an overview of CDK/inhibitor co-crystal structures. Eur J Med Chem. 2019;164:615–639.
   PubMed Web of Science ®Google Scholar
• Bradner JE, Hnisz D, Young RA. Transcriptional addiction in cancer. Cell. 2017;168(4):629–643.
   PubMed Web of Science ®Google Scholar
• Galbraith MD, Bender H, Espinosa JM. Therapeutic targeting of transcriptional cyclin-dependent kinases. Transcription. 2019;10(2):118–136.
   PubMed Web of Science ®Google Scholar
• Yu Z, Du JY, Zhao Y, et al. A novel kinase inhibitor, LZT-106, downregulates Mcl-1 and sensitizes colorectal cancer cells to BH3 mimetic ABT-199 by targeting CDK9 and GSK-3 beta signaling. Cancer Lett. 2021;498:31–41.
   PubMed Web of Science ®Google Scholar
• Danilov A, Rowland T, Paiva C, et al. Selective targeting cyclin-dependent kinase-9 (CDK9) antagonizes survival of neoplastic B-cells via deregulation of c-MYC and MCL-1. Leuk Lymphoma. 2017;58:25–26.
   Web of Science ®Google Scholar
• Huang WL, Abudureheman T, Xia J, et al. CDK9 inhibitor induces the apoptosis of B-Cell acute lymphocytic leukemia by inhibiting c-Myc-mediated glycolytic metabolism. Front Cell Dev Biol. 2021;9:641271.
   PubMed Web of Science ®Google Scholar
• Zhang HH, Pandey S, Travers M, et al. Targeting CDK9 reactivates epigenetically silenced genes in cancer. Cell. 2018;175(5):1244. DOI:10.1016/j.cell.2018.09.051
   PubMed Web of Science ®Google Scholar
• Bhurta D, Bharate SB. Analyzing the scaffold diversity of cyclin-dependent kinase inhibitors and revisiting the clinical and preclinical pipeline. Med Res Rev. 2022;42(2):654–709.
   PubMed Web of Science ®Google Scholar
• Asghar U, Witkiewicz AK, Turner NC, et al. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov. 2015;14(2):130–146. DOI:10.1038/nrd4504
   PubMed Web of Science ®Google Scholar
• Wu T, Qin Z, Tian Y, et al. Recent developments in the biology and medicinal chemistry of CDK9 inhibitors: an update. J Med Chem. 2020;63(22):13228–13257. DOI:10.1021/acs.jmedchem.0c00744
   PubMed Web of Science ®Google Scholar
• Alsfouk A. Small molecule inhibitors of cyclin-dependent kinase 9 for cancer therapy. J Enzyme Inhib Med Chem. 2021;36(1):693–706.
   PubMed Web of Science ®Google Scholar
• Huang Z, Wang T, Wang C, et al. CDK9 inhibitors in cancer research. RSC Med Chem. 2022;13(6):688–710. DOI:10.1039/D2MD00040G
   PubMedGoogle Scholar
• Bacon CW, D’Orso I. CDK9: a signaling hub for transcriptional control. Transcription. 2019;10(2):57–75.
   PubMed Web of Science ®Google Scholar
• Mandal R, Becker S, Strebhardt K. Targeting CDK9 for anti-cancer therapeutics. Cancers (Basel). 2021;13(9). DOI:10.3390/cancers13092181
   Web of Science ®Google Scholar
• Mbonye UR, Gokulrangan G, Datt M, et al. Phosphorylation of CDK9 at Ser175 enhances HIV transcription and is a marker of activated P-TEFb in CD4(+) T lymphocytes. PLOS Pathog. 2013;9(5):e1003338. DOI:10.1371/journal.ppat.1003338
   PubMed Web of Science ®Google Scholar
• Clopper KC, Taatjes DJ. Chemical inhibitors of transcription-associated kinases. Curr Opin Chem Biol. 2022;70:102186.
   PubMed Web of Science ®Google Scholar
• Troiani M, Colucci M, D’Ambrosio M, et al. Single-cell transcriptomics identifies Mcl-1 as a target for senolytic therapy in cancer. Nat Commun. 2022;13(1):2177. DOI:10.1038/s41467-022-29824-1
   PubMed Web of Science ®Google Scholar
• Hsieh MJ, Hsieh YH, Lin CW, et al. Transcriptional regulation of Mcl-1 plays an important role of cellular protective effector of vincristine-triggered autophagy in oral cancer cells. Expert Opin Ther Targets. 2015;19(4):455–470. DOI:10.1517/14728222.2014.998200
   PubMed Web of Science ®Google Scholar
• Jin YP, Qiu JP, Lu XF, et al. C-MYC inhibited ferroptosis and promoted immune evasion in ovarian cancer cells through NCOA4 mediated ferritin autophagy. Cells. 2022;11(24):4127. DOI:10.3390/cells11244127.
   PubMed Web of Science ®Google Scholar
• Park M, Cho JH, Moon B, et al. CDK9 inhibitors downregulate DKK1 expression to suppress the metastatic potential of HCC cells. Genes Genomics. 2023;45(3):285–293. DOI:10.1007/s13258-022-01351-9
   PubMed Web of Science ®Google Scholar
• Xu Z, Zhang B, Liu Z, et al. Design, synthesis and anticancer evaluation of selective 2,4-disubstituted pyrimidine CDK9 inhibitors. Eur J Med Chem. 2022;244:114875.
   PubMed Web of Science ®Google Scholar
• Wang XR, Liu XY, Huang JH, et al. Discovery of 2H-benzo[b][1,4]oxazin-3(4H)-one derivatives as potent and selective CDK9 inhibitors that enable transient target engagement for the treatment of hematologic malignancies. Eur J Med Chem. 2022;238:114461.
   PubMed Web of Science ®Google Scholar
• Passalacqua MI, Rizzo G, Santarpia MC, et al. Why is survival with triple negative breast cancer so low? insights and talking points from preclinical and clinical research. Expert Opin Investig Drugs. 2022;31(12):1291–1310. DOI:10.1080/13543784.2022.2159805
   PubMed Web of Science ®Google Scholar
• Cheng S, Yang GJ, Wang W, et al. Discovery of a tetrahydroisoquinoline-based CDK9-cyclin T1 protein-protein interaction inhibitor as an anti-proliferative and anti-migration agent against triple-negative breast cancer cells. Genes Dis. 2022;9(6):1674–1688. DOI:10.1016/j.gendis.2021.06.005
   PubMed Web of Science ®Google Scholar
• Brisard D, Eckerdt F, Marsh LA, et al. Antineoplastic effects of selective CDK9 inhibition with atuveciclib on cancer stem-like cells in triple-negative breast cancer. Oncotarget. 2018;9(99):37305–37318. DOI:10.18632/oncotarget.26468
   PubMedGoogle Scholar
• Winter JM, Mustafa EH, Wang SD, et al. Novel and highly selective CDK9 inhibitors suppress proliferation of triple negative breast cancer (TNBC) cells in vitro. Cancer Res. 2019;79(13):4433. DOI:10.1158/1538-7445.AM2019-4433
   Web of Science ®Google Scholar
• Cheng SS, Qu YQ, Wu J, et al. Inhibition of the CDK9-cyclin T1 protein-protein interaction as a new approach against triple-negative breast cancer. Acta Pharm Sin B. 2022;12(3):1390–1405. DOI:10.1016/j.apsb.2021.10.024
   PubMed Web of Science ®Google Scholar
• Wei D, Wang HL, Zeng QH, et al. Discovery of potent and selective CDK9 degraders for targeting transcription regulation in triple-negative breast cancer. J Med Chem. 2021;64(19):14822–14847. DOI:10.1021/acs.jmedchem.1c01350
   PubMed Web of Science ®Google Scholar
• Zhao W, Zhang L, Zhang Y, et al. The CDK inhibitor AT7519 inhibits human glioblastoma cell growth by inducing apoptosis, pyroptosis and cell cycle arrest. Cell Death Dis. 2023;14(1):11. DOI:10.1038/s41419-022-05528-8
   PubMed Web of Science ®Google Scholar
• Chin L, Meyerson M, Aldape K, et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455(7216):1061–1068.
   PubMed Web of Science ®Google Scholar
• El Atat O, Naser R, Abdelkhalek M, et al. Molecular targeted therapy: a new avenue in glioblastoma treatment. Oncol Lett. 2023;25(2):46. DOI:10.3892/ol.2022.13632
   PubMed Web of Science ®Google Scholar
• Ranjan A, Pang Y, Butler M, et al. Targeting CDK9 for the treatment of glioblastoma. Cancers (Basel). 2021;13(12):3039. DOI:10.3390/cancers13123039
   PubMed Web of Science ®Google Scholar
• Qiu Z, Zhao L, Shen JZ, et al. Transcription elongation machinery is a druggable dependency and potentiates immunotherapy in glioblastoma stem cells. Cancer Discov. 2022;12(2):502–521. DOI:10.1158/2159-8290.CD-20-1848
   PubMed Web of Science ®Google Scholar
• Xie Q, Wu Q, Kim L, et al. RBPJ maintains brain tumor-initiating cells through CDK9-mediated transcriptional elongation. J Clin Invest. 2016;126(7):2757–2772. DOI:10.1172/JCI86114
   PubMed Web of Science ®Google Scholar
• Aurilio G, Cimadamore A, Mazzucchelli R, et al. Androgen receptor signaling pathway in prostate cancer: from genetics to clinical applications. Cells. 2020;9(12):2653.
   PubMed Web of Science ®Google Scholar
• Gao X, Liang J, Wang L, et al. Phosphorylation of the androgen receptor at Ser81 is co-sustained by CDK1 and CDK9 and leads to AR-mediated transactivation in prostate cancer. Mol Oncol. 2021;15(7):1901–1920. DOI:10.1002/1878-0261.12968
   PubMed Web of Science ®Google Scholar
• Gordon V, Bhadel S, Wunderlich W, et al. CDK9 regulates AR promoter selectivity and cell growth through serine 81 phosphorylation. Mol Endocrinol. 2010;24(12):2267–2280. DOI:10.1210/me.2010-0238
   PubMed Web of Science ®Google Scholar
• Pallasaho S, Gondane A, Kuivalainen A, et al. Castration-resistant prostate cancer cells are dependent on the high activity of CDK7. J Cancer Res Clin Oncol. 2022. doi: 10.1007/s00432-022-04475-3.
   PubMed Web of Science ®Google Scholar
• Richters A, Doyle SK, Freeman DB, et al. Modulating androgen receptor-driven transcription in prostate cancer with selective CDK9 inhibitors. Cell Chem Biol. 2021;28(2):134–147. DOI:10.1016/j.chembiol.2020.10.001
   PubMed Web of Science ®Google Scholar
• Amrhein JA, Beyett TS, Feng WW, et al. Macrocyclization of quinazoline-based EGFR inhibitors leads to exclusive mutant selectivity for EGFR L858R and Del19. J Med Chem. 2022;65(23):15679–15697. DOI:10.1021/acs.jmedchem.2c01041
   PubMed Web of Science ®Google Scholar
• Obst-Sander U, Ricci A, Kuhn B, et al. Discovery of novel allosteric EGFR L858R inhibitors for the treatment of non-small-cell lung cancer as a single agent or in combination with osimertinib. J Med Chem. 2022;65(19):13052–13073. DOI:10.1021/acs.jmedchem.2c00893
   PubMed Web of Science ®Google Scholar
• Xu L, Xu B, Wang JS, et al. Recent advances of novel fourth generation EGFR inhibitors in overcoming C797S mutation of lung cancer therapy. Eur J Med Chem. 2023;245:114900.
   PubMed Web of Science ®Google Scholar
• Yang LH, Zhou F, Zhuang Y, et al. Acetyl-bufalin shows potent efficacy against non-small-cell lung cancer by targeting the CDK9/STAT3 signalling pathway. Br J Cancer. 2021;124(3):645–657. DOI:10.1038/s41416-020-01135-6
   PubMed Web of Science ®Google Scholar
• Padmanabhan J, Saha B, Powell C, et al. Inhibitors targeting CDK9 show high efficacy against osimertinib and AMG510 resistant lung adenocarcinoma cells. Cancers (Basel). 2021;13(15):3906. DOI:10.3390/cancers13153906
   PubMed Web of Science ®Google Scholar
• Pollyea DA, Bixby D, Perl A, et al. NCCN guidelines insights: acute myeloid leukemia, version 2.2021. J Natl Compr Canc Netw. 2021;19(1):16–27. DOI:10.6004/jnccn.2021.0002
   PubMed Web of Science ®Google Scholar
• Xu J, Li H, Wang X, et al. Discovery of coumarin derivatives as potent and selective cyclin-dependent kinase 9 (CDK9) inhibitors with high antitumour activity. Eur J Med Chem. 2020;200:112424.
   PubMed Web of Science ®Google Scholar
• Wang J, Li T, Zhao T, et al. Design of wogonin-inspired selective cyclin-dependent kinase 9 (CDK9) inhibitors with potent in vitro and in vivo antitumor activity. Eur J Med Chem. 2019;178:782–801.
   PubMed Web of Science ®Google Scholar
• Zhang J, Wang Y, Yin C, et al. Artesunate improves venetoclax plus cytarabine AML cell targeting by regulating the Noxa/Bim/Mcl-1/p-Chk1 axis. Cell Death Dis. 2022;13(4):379. DOI:10.1038/s41419-022-04810-z
   PubMed Web of Science ®Google Scholar
• Liu F, Zhao Q, Su Y, et al. Cotargeting of Bcl-2 and Mcl-1 shows promising antileukemic activity against AML cells including those with acquired cytarabine resistance. Exp Hematol. 2022;105:39–49.
   PubMed Web of Science ®Google Scholar
• Fernandez-Marrero Y, Spinner S, Kaufmann T, et al. Survival control of malignant lymphocytes by anti-apoptotic MCL-1. Leukemia. 2016;30(11):2152–2159. DOI:10.1038/leu.2016.213
   PubMed Web of Science ®Google Scholar
• Fiskus W, Manshouri T, Birdwell C, et al. Efficacy of CDK9 inhibition in therapy of post-myeloproliferative neoplasm (MPN) secondary (s) AML cells. Blood Cancer J. 2022;12(1):23. DOI:10.1038/s41408-022-00618-4
   PubMed Web of Science ®Google Scholar
• Sher S, Whipp E, Walker J, et al. VIP152 is a selective CDK9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemia. Leukemia. 2023;37(2):326–338. DOI:10.1038/s41375-022-01758-z
   PubMed Web of Science ®Google Scholar
• He XL, Hu YH, Chen JM, et al. SNS-032 attenuates liver fibrosis by anti-active hepatic stellate cells via inhibition of cyclin dependent kinase 9. Front Pharmacol. 2022;13:1016552.
   PubMed Web of Science ®Google Scholar
• Parvathareddy SK, Siraj AK, Masoodi T, et al. Cyclin-dependent kinase 9 (CDK9) predicts recurrence in Middle Eastern epithelial ovarian cancer. J Ovarian Res. 2021;14(1):69. DOI:10.1186/s13048-021-00827-8
   PubMed Web of Science ®Google Scholar
• Li J, Zhi X, Chen S, et al. CDK9 inhibitor CDKI-73 is synergetic lethal with PARP inhibitor olaparib in BRCA1 wide-type ovarian cancer. Am J Cancer Res. 2020;10(4):1140–1155.
   PubMed Web of Science ®Google Scholar
• Guhan SM, Shaughnessy M, Rajadurai A, et al. The molecular context of vulnerability for CDK9 suppression in triple wild-type melanoma. J Invest Dermatol. 2021;141(8):2018–2027. DOI:10.1016/j.jid.2020.12.035
   PubMed Web of Science ®Google Scholar
• Zhang Y, Hou J, Shi S, et al. CSN6 promotes melanoma proliferation and metastasis by controlling the UBR5-mediated ubiquitination and degradation of CDK9. Cell Death Dis. 2021;12(1):118. DOI:10.1038/s41419-021-03398-0
   PubMed Web of Science ®Google Scholar
• Fleischmann M, Mandal R, Kostova I, et al. Prognostic impact of caspase-8, CDK9 and phospho-CDK9 (Thr 186) expression in patients with uterine cervical cancer treated with definitive chemoradiation and brachytherapy. Cancers (Basel). 2022;14(22):5500. DOI:10.3390/cancers14225500
   PubMed Web of Science ®Google Scholar
• Mandal R, Raab M, Rodel F, et al. The non-apoptotic function of caspase-8 in negatively regulating the CDK9-mediated Ser2 phosphorylation of RNA polymerase II in cervical cancer. Cell Mol Life Sci. 2022;79(12):597. DOI:10.1007/s00018-022-04598-3
   PubMed Web of Science ®Google Scholar
• Ma H, Seebacher NA, Hornicek FJ, et al. Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in osteosarcoma. EBioMedicine. 2019;39:182–193.
   PubMed Web of Science ®Google Scholar
• Borowczak J, Szczerbowski K, Maniewski M, et al. The prognostic role of CDK9 in bladder cancer. Cancers (Basel). 2022;14(6):1492. DOI:10.3390/cancers14061492
   PubMed Web of Science ®Google Scholar
• Anshabo AT, Milne R, Wang SD, et al. CDK9: a comprehensive review of its biology, and its role as a potential target for anti-cancer agents. Front Oncol. 2021;11:678559.
   PubMed Web of Science ®Google Scholar
• Lucking U, Scholz A, Lienau P, et al. Identification of atuveciclib (BAY 1143572), the first highly selective, clinical PTEFB/CDK9 inhibitor for the treatment of cancer. ChemMedchem. 2017;12(21):1776–1793. DOI:10.1002/cmdc.201700447
   PubMed Web of Science ®Google Scholar
• Lucking U, Kosemund D, Bohnke N, et al. Changing for the better: discovery of the highly potent and selective CDK9 inhibitor VIP152 suitable for once weekly intravenous dosing for the treatment of cancer. J Med Chem. 2021;64(15):11651–11674. DOI:10.1021/acs.jmedchem.1c01000
   PubMed Web of Science ®Google Scholar
• Barlaam B, De Savi C, Dishington A, et al. Discovery of a series of 7-azaindoles as potent and highly selective CDK9 inhibitors for transient target engagement. J Med Chem. 2021;64(20):15189–15213. DOI:10.1021/acs.jmedchem.1c01249
   PubMed Web of Science ®Google Scholar
• Cidado J, Boiko S, Proia T, et al. AZD4573 is a highly selective CDK9 inhibitor that suppresses MCL-1 and induces apoptosis in hematologic cancer cells. Clin Cancer Res. 2020;26(4):922–934. DOI:10.1158/1078-0432.CCR-19-1853
   PubMed Web of Science ®Google Scholar
• Zhao Z, Wu S, Liu Y, et al., inventors; Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Yangtze River Pharmaceutical Group Co., Ltd, assignee. Substituted bis(pyridin-2-yl)amine derivative, composition thereof and medical use thereof patent WO2022078309. 2022.
   Google Scholar
• Liu Q, Liu J, Wu Y, et al., inventors; Hefei Institutes of Physical Science, Chinese Academy of Sciences, assignee. Preparation of dihydroisoquinolone and isoindolinone derivatives as CDK9 inhibitors patent CN114516856. 2022.
   Google Scholar
• Wang S, Long Y, Yu M, et al., inventors; Aucentra Therapeutics Pty Ltd, assignee. Preparation of derivatives of 4-(imidazo[1,2-a]pyridin-3-yl)-N-(pyridin-3-yl)pyrimidin-2-amine for treating proliferative diseases and conditions patent WO2021072475. 2021.
   Google Scholar
• Li Z, Bian J, Wu T, et al., inventors; China Pharmaceutical University, assignee. Preparation and application of aminopyrimidine derivative selectively targeting cdk9 patent WO2023005280. 2023.
   Google Scholar
• Bian J, Li Z, Wu T, et al., inventors; China Pharmaceutical University, assignee. Preparation method for and application of novel cdk9 inhibitor having macrocyclic skeleton structure patent WO2023005281. 2023.
   Google Scholar
• Barlaam B, Casella R, Cidado J, et al. Discovery of AZD4573, a potent and selective inhibitor of CDK9 that enables short duration of target engagement for the treatment of hematological malignancies. J Med Chem. 2020;63(24):15564–15590. DOI:10.1021/acs.jmedchem.0c01754
   PubMed Web of Science ®Google Scholar
• Boiko S, Proia T, San Martin M, et al. Transient CDK9 inhibition with AZD4573 modulates Bfl-1 in preclinical lymphoma models. Cancer Res. 2019;79(13):2500. DOI:10.1158/1538-7445.AM2019-2500
   Web of Science ®Google Scholar
• Cidado J, Proia T, Boiko S, et al. AZD4573, a novel CDK9 inhibitor, rapidly induces cell death in hematological tumor models through depletion of Mcl1. Cancer Res. 2018;78(13):310. DOI:10.1158/1538-7445.AM2018-310
   Web of Science ®Google Scholar
• U.S. National library of medicine: ClinicalTrials.Gov. Available from https://www.clinicaltrials.gov . [cited Feb 19, 2023]
   Google Scholar
• Wang Z, Zhang Y, Mu Y, et al., inventors; CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd, assignee. Preparation of the heterocyclic analogues and their application as cyclin-dependent kinase 9 inhibitors patent WO2021115335. 2021.
   Google Scholar
• Zheng S, Xie C, Zheng M, et al., inventors; Suzhou Alphama Biotech Co., Ltd, assignee. Polycyclic amide derivatives as CDK9 inhibitors, its preparation method, and its application in treating of cancer patent CN113149996. 2021.
   Google Scholar
• Zheng S, Xie C, Zheng M, et al., inventors; Suzhou Alphama Biotech Co., Ltd. assignee. Preparation of ((aryl)chloropyridyl)acetamides as CDK inhibitor patent CN113173924. 2021.
   Google Scholar
• Wan H, Zha C, Wang Y, et al., inventors; Shanghai Ringene Biopharma Co., Ltd. Shanghai Lingji Biological Technology Co., Ltd, assignee. Preparation of pyrimidine-based compounds having CDK kinase inhibitory activity, pharmaceutical compositions and its application patent CN114605390. 2022.
   Google Scholar
• Lu L, Shetty R, Combs AP, et al. Prelude therapeutics incorporated, assignee. Preparation of indazolyl-pyrimidines and related heterocycles as CDK inhibitors and their use as pharmaceuticals patent US20210070761. 2021. inventors
   Google Scholar
• Zhao Z, Wu S, Hua M, et al., inventors; Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Yangtze River Pharmaceutical Group Co., Ltd, assignee. Substituted pyrazolo[1,5-a]pyrimidine-7-amine derivative, compositions and medical use patent WO2022156779. 2022.
   Google Scholar
• Mikochik P, Vacca J, Freeman D, et al., inventors; Kronos Bio, Inc., assignee. Preparation of pyrazolopyrimidines, compositions with them, as CDK9 activity modulators useful in treatment of CDK9-mediated diseases patent US20200131189. 2020.
   Google Scholar
• Huang Y, Jiang C, Yu H, et al., inventors; Shenzhen Bay Laboratory Pingshan Biomedical R&D and Transformation Center Peking University Shenzhen Graduate School Shenzhen Rongxin Biotechnology Co., Ltd., assignee. Compound as CDK9 kinase inhibitor and preparation and pharmaceutical composition thereof patent CN112125911. 2020.
   Google Scholar
• Li Y, Quan Y, Wang Y, et al., inventors; Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, assignee. Preparation of pyrrolo[2,3-d]pyrimidine derivatives as CDK4, 6 or 9 inhibitors and used as antitumor agents patent CN112375081. 2021.
   Google Scholar
• Liu Y, Xu Z, Hu L, et al., inventors; Medshine Discovery Inc, assignee. Azaindole pyrazole compounds as CDK9 inhibitors patent WO2020259556. 2020.
   Google Scholar
• Spyvee MR, Kallenbach JM, Gupta A, et al., inventors; Reverie Labs, Inc, assignee. Naphtho[2,1-d]thiazole derivatives, compositions thereof and methods of treating disorders and their preparation patent WO2021102410. 2021.
   Google Scholar
• Han X, Song N, Saidahmatov A, et al. Rational design and development of novel CDK9 inhibitors for the treatment of acute myeloid leukemia. J Med Chem. 2021;64(19):14647–14663. DOI:10.1021/acs.jmedchem.1c01148
   PubMed Web of Science ®Google Scholar
• Verma J, Khedkar VM, Coutinho EC. 3D-QSAR in drug design–a review. Curr Top Med Chem. 2010;10(1):95–115.
   PubMed Web of Science ®Google Scholar
• Moffat JG, Rudolph J, Bailey D. Phenotypic screening in cancer drug discovery - past, present and future. Nat Rev Drug Discov. 2014;13(8):588–602.
   PubMed Web of Science ®Google Scholar
• Butera JA. Phenotypic screening as a strategic component of drug discovery programs targeting novel antiparasitic and antimycobacterial agents: an editorial miniperspectives series on phenotypic screening for antiinfective targets. J Med Chem. 2013;56(20):7715–7718.
   PubMed Web of Science ®Google Scholar
• Garber K. The PROTAC gold rush. Nat Biotechnol. 2022;40(1):12–16.
   PubMed Web of Science ®Google Scholar
• Li J, Liu T, Song Y, et al. Discovery of small-molecule degraders of the CDK9-cyclin T1 complex for targeting transcriptional addiction in prostate cancer. J Med Chem. 2022;65(16):11034–11057. DOI:10.1021/acs.jmedchem.2c00257
   PubMed Web of Science ®Google Scholar